PIPELINE

Vaccines Pipeline

logo Vaxdyn blanco-verde

Vaccines Pipeline

We are committed to developing a vaccines’ pipeline against the most worrisome bacteria because of their capacity of resistance to all or nearly all available antibiotics

Vaxdin-hero

PRODUCTS

K-Vax

Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Klebsiella pneumoniae.

Stage: Pre-clinical development

Indication: Raise active immunity against 100% of circulating strains of K. pneumoniae and A. baumannii, in the population in hospitals or the community at risk of developing infections by K. pneumoniae and A. baumannii.

Highlights: Multivalent vaccine candidate of Vaxdyn’s technological platform. First proof of principle in humans expected in 2025. Product powered by the global accelerator CARB-X.

P-Vax

Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Pseudomonas aeruginosa.

Stage: Pre-clinical development

Indication: Raise active immunity against 100% of circulating strains of P. aeruginosa and A. baumannii, in the population in hospitals or the community at risk of developing infections by P. aeruginosa and A. baumannii.

AcinetoVax

Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine.

Stage: Pre-clinical development

Indication: Raise active immunity against 100% of circulating strains of Acinetobacter baumannii, in the population in hospitals or the community at risk of developing infections by A. baumannii.

EcoVax

Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Extraintestinal Pathogenic Escherichia coli (ExPEC).

Stage: Lead Optimization.

Indication: Raise active immunity against 100% of circulating strains of ExPEC and A. baumannii, in the community at risk of developing infections by ExPEC and A. baumannii.

AppeVax

Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Actinobacillus pleuropneumoniae.

Stage: Lead Optimization.

Indication: A vaccine for prevention of porcine pleuropneumonia caused by the pig respiratory pathogens A. pleuropneumoniae.

CONTACT

Vaxdyn

Supported by

CONTACT US


Vaxdyn logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.